We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-24.15%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.88B
AUM Growth
-$596M
Cap. Flow
+$67.8M
Cap. Flow %
3.61%
Top 10 Hldgs %
70.78%
Holding
37
New
1
Increased
21
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$34.8M
2
STAA icon
STAAR Surgical
STAA
+$24.4M
3
FOLD
Amicus Therapeutics
FOLD
+$11.4M
4
CELG
Celgene Corp
CELG
+$7.63M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.64M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$25.3M
2
ABMD
Abiomed Inc
ABMD
+$6.73M
3
TRVN
Trevena, Inc.
TRVN
+$724K

Sector Composition

Rank Sector Weight
1 Healthcare 91.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
1
DELISTED
Abiomed Inc
ABMD
$224M 11.93%
689,550
-19,367
-3% -$6.73M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$12.5B
$218M 11.6%
2,559,733
+10,302
+0.4% +$980K
UTHR icon
3
United Therapeutics
UTHR
$22.8B
$178M 9.46%
1,632,025
+6,791
+0.4% +$787K
STAA icon
4
STAAR Surgical
STAA
$1.26B
$132M 7.05%
4,147,988
+626,423
+18% +$24.4M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$117M 6.24%
1,204,328
+4,127
+0.3% +$488K
VNDA icon
6
Vanda Pharmaceuticals
VNDA
$297M
$109M 5.78%
4,155,670
– –
INSM icon
7
Insmed
INSM
$28.9B
$100M 5.35%
7,653,617
+296,334
+4% +$4.73M
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$94.1M 5.01%
5,239,304
+18,278
+0.4% +$373K
SAGE
9
DELISTED
Sage Therapeutics
SAGE
$81.5M 4.34%
850,977
+10,605
+1% +$1.21M
WMGI
10
DELISTED
Wright Medical Group Inc
WMGI
$75.4M 4.02%
2,771,394
+13,807
+0.5% +$382K
IMMU
11
DELISTED
Immunomedics Inc
IMMU
$74M 3.94%
5,186,255
+172,491
+3% +$3.42M
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
$70.9M 3.77%
7,401,321
+1,035,174
+16% +$11.4M
AMAG
13
DELISTED
AMAG Pharmaceuticals
AMAG
$51.4M 2.73%
3,380,506
– –
KPTI icon
14
Karyopharm Therapeutics
KPTI
$44.2M
$43.9M 2.34%
312,357
+1,469
+0.5% +$248K
EPZM
15
DELISTED
Epizyme, Inc
EPZM
$42.7M 2.27%
6,935,074
+28,916
+0.4% +$221K
CELG
16
DELISTED
Celgene Corp
CELG
$34.1M 1.82%
532,667
+103,400
+24% +$7.63M
AIMT
17
DELISTED
Aimmune Therapeutics
AIMT
$33.2M 1.77%
1,387,589
+5,830
+0.4% +$151K
ALGN icon
18
Align Technology
ALGN
$12.4B
$32.8M 1.75%
156,823
+9,016
+6% +$2.28M
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$5.06B
$32.8M 1.74%
2,026,063
+341,883
+20% +$6.64M
PBYI icon
20
Puma Biotechnology
PBYI
$450M
$23.6M 1.26%
+1,159,900
New +$34.8M
MNTA
21
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$20.3M 1.08%
1,841,613
+8,081
+0.4% +$112K
EXAS
22
DELISTED
Exact Sciences
EXAS
$19.9M 1.06%
314,889
+1,569
+0.5% +$108K
ALDR
23
DELISTED
Alder Biopharmaceuticals
ALDR
$19.1M 1.02%
1,861,630
+8,529
+0.5% +$109K
PRTA icon
24
Prothena Corp
PRTA
$438M
$11.4M 0.61%
1,108,510
+5,185
+0.5% +$61.6K
GILD icon
25
Gilead Sciences
GILD
$165B
$11M 0.59%
175,900
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM

Palo Alto Investors's Q4 2018 Portfolio in Review

As of Q4 2018, Palo Alto Investors held 37 positions worth $1.88B, down 24% from $2.47B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Palo Alto Investors deployed $67.8M of net new capital in Q4 2018, opening 1 new position and adding to 21 existing holdings. Its largest new stake was Puma Biotechnology: 1,159,900 shares worth $23.6M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was Shire pic, an estimated $25.3M trimmed.

  • Palo Alto Investors's largest Q4 2018 buy was Puma Biotechnology: 1,159,900 shares worth $23.6M.
  • Palo Alto Investors added most to STAAR Surgical in Q4 2018, an estimated $24.4M increase.
  • Palo Alto Investors's biggest Q4 2018 reduction was Shire pic, cutting an estimated $25.3M.
  • Palo Alto Investors fully exited Trevena, Inc. in Q4 2018, selling an estimated $724K.
  • Palo Alto Investors's ten largest holdings make up 71% of its $1.88B portfolio in Q4 2018.
  • Palo Alto Investors opened 1 new position and closed 1 in Q4 2018.
  • Palo Alto Investors's portfolio value fell 24% quarter-over-quarter to $1.88B.

Based on Palo Alto Investors's 13F filing for Q4 2018, filed 14 Feb 2019.